Comparative efficacy of double plasma molecular adsorption system combined with plasma exchange versus plasma exchange in treating acute-on-chronic liver failure due to hepatitis B: A meta-analysis

IF 1.4 4区 医学 Q4 HEMATOLOGY
Le Zhang, Yan Ma, Xia Wang, Li-Na Ma, Wanlong Ma, Xiang-Chun Ding
{"title":"Comparative efficacy of double plasma molecular adsorption system combined with plasma exchange versus plasma exchange in treating acute-on-chronic liver failure due to hepatitis B: A meta-analysis","authors":"Le Zhang,&nbsp;Yan Ma,&nbsp;Xia Wang,&nbsp;Li-Na Ma,&nbsp;Wanlong Ma,&nbsp;Xiang-Chun Ding","doi":"10.1002/jca.22140","DOIUrl":null,"url":null,"abstract":"<p>This meta-analysis aims to evaluate the effectiveness of the double plasma molecular adsorption system (DPMAS) in combination with plasma exchange (PE) compared to plasma exchange alone in the treatment of Acute-on-Chronic liver failure (LF) caused by hepatitis B. Until August 31, 2023, a comprehensive search of databases including Embase, Chinese Medical Journal Full-text Database, China Biomedical Literature Database, Wan Fang Medical Network, PubMed, and the Cochrane Library was carried out using keywords like “liver failure,” “acute-on-chronic liver failure,” “PE,” “DPMAS,” and related terms. The quality of the included studies was evaluated using QUADS (quality assessment of diagnostic accuracy studies). Software Revman 5.3 was used to examine the data, while Stata 15.1 was used to run Egger's test. Following thorough screening, 452 patients who received PE alone and 429 patients who received DPMAS in addition to PE were included. Every study that was included was of a high caliber. When comparing the DPMAS plus PE group to the PE alone group, the total bilirubin reduction was considerably higher (mean difference [MD] = −49.09, 95% confidence interval [CI]: −54.84 to −43.35, <i>p</i> &lt; .00001). Prothrombin activity (PTA; MD = −1.53, 95% CI: −3.29 to −0.22, <i>p</i> = .09), albumin (ALB; MD = −0.58, 95% CI: −1.57 to 0.41, <i>p</i> = .25), prothrombin time (PT; MD = −0.07, 95% CI: −1.47 to 1.34, <i>p</i> = .92), and platelet count (PLT; MD = −0.08, 95% CI: −1.33 to 1.66, <i>p</i> = .90) did not differ significantly. The improvement in international standardized ratio (INR) was significantly greater in the PE group (MD = 0.07, 95% CI (0.03, 0.10), <i>p</i> = .0001). When combined with DPMAS, PE has been shown to be more effective in lowering total bilirubin levels. PE can also lower INR in individuals who have hepatitis B-related ACLF. This therapeutic strategy also lessens the need for plasma transfusions.</p>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jca.22140","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Apheresis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jca.22140","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This meta-analysis aims to evaluate the effectiveness of the double plasma molecular adsorption system (DPMAS) in combination with plasma exchange (PE) compared to plasma exchange alone in the treatment of Acute-on-Chronic liver failure (LF) caused by hepatitis B. Until August 31, 2023, a comprehensive search of databases including Embase, Chinese Medical Journal Full-text Database, China Biomedical Literature Database, Wan Fang Medical Network, PubMed, and the Cochrane Library was carried out using keywords like “liver failure,” “acute-on-chronic liver failure,” “PE,” “DPMAS,” and related terms. The quality of the included studies was evaluated using QUADS (quality assessment of diagnostic accuracy studies). Software Revman 5.3 was used to examine the data, while Stata 15.1 was used to run Egger's test. Following thorough screening, 452 patients who received PE alone and 429 patients who received DPMAS in addition to PE were included. Every study that was included was of a high caliber. When comparing the DPMAS plus PE group to the PE alone group, the total bilirubin reduction was considerably higher (mean difference [MD] = −49.09, 95% confidence interval [CI]: −54.84 to −43.35, p < .00001). Prothrombin activity (PTA; MD = −1.53, 95% CI: −3.29 to −0.22, p = .09), albumin (ALB; MD = −0.58, 95% CI: −1.57 to 0.41, p = .25), prothrombin time (PT; MD = −0.07, 95% CI: −1.47 to 1.34, p = .92), and platelet count (PLT; MD = −0.08, 95% CI: −1.33 to 1.66, p = .90) did not differ significantly. The improvement in international standardized ratio (INR) was significantly greater in the PE group (MD = 0.07, 95% CI (0.03, 0.10), p = .0001). When combined with DPMAS, PE has been shown to be more effective in lowering total bilirubin levels. PE can also lower INR in individuals who have hepatitis B-related ACLF. This therapeutic strategy also lessens the need for plasma transfusions.

Abstract Image

双血浆分子吸附系统联合血浆置换术与血浆置换术治疗乙型肝炎急性-慢性肝功能衰竭的疗效比较:一项荟萃分析。
本荟萃分析旨在评估双血浆分子吸附系统(DPMAS)联合血浆置换术(PE)与单纯血浆置换术治疗乙型肝炎引起的急性慢性肝功能衰竭(LF)的有效性。截至 2023 年 8 月 31 日,使用关键词 "肝衰竭"、"急性慢性肝衰竭"、"PE"、"DPMAS "及相关术语对 Embase、中华医学杂志全文数据库、中国生物医学文献数据库、万方医学网、PubMed 和 Cochrane 图书馆等数据库进行了全面检索。纳入研究的质量采用 QUADS(诊断准确性研究质量评估)进行评估。研究数据使用 Revman 5.3 软件,Egger 检验使用 Stata 15.1。经过全面筛选,452 名仅接受 PE 治疗的患者和 429 名除接受 PE 治疗外还接受 DPMAS 治疗的患者被纳入研究范围。每项纳入的研究都具有很高的水准。将 DPMAS 加 PE 组与单纯 PE 组相比,总胆红素的降低幅度要高得多(平均差 [MD] = -49.09,95% 置信区间 [CI]:-54.84 至 -43.35,P.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
13.30%
发文量
70
审稿时长
>12 weeks
期刊介绍: The Journal of Clinical Apheresis publishes articles dealing with all aspects of hemapheresis. Articles welcomed for review include those reporting basic research and clinical applications of therapeutic plasma exchange, therapeutic cytapheresis, therapeutic absorption, blood component collection and transfusion, donor recruitment and safety, administration of hemapheresis centers, and innovative applications of hemapheresis technology. Experimental studies, clinical trials, case reports, and concise reviews will be welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信